Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00089245 · ClinicalTrials.gov registry record · Phase 1
Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
A Phase 1 study, sponsored by Y-mAbs Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 177
- Enrollment target
NCT00089245 is a Phase 1 study that was terminated before completion, run by Y-mAbs Therapeutics. The registered enrollment target is 177 participants.
The verdict
NCT00089245, a Phase 1 study, was terminated before completion, sponsored by Y-mAbs Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 177 participants
- Enrollment target
Study Summary
The purpose of this study is to test the feasibility and toxicity of administering intrathecal immunotherapy for patients with central nervous system/leptomeningeal (CNS/LM) malignancies.
Interventions
- DRUG Iodine I 131 MOAB 8H9
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2004-02-05 |
| Est. Completion | 2022-02-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00089245
The ClinicalTrials.gov registry entry for NCT00089245 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 177 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Y-mAbs Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Iodine I 131 MOAB 8H9 is the first listed.
NCT00089245 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00089245 about?
NCT00089245 is a clinical study titled "Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer". The purpose of this study is to test the feasibility and toxicity of administering intrathecal immunotherapy for patients with central nervous system/leptomeningeal (CNS/LM) malignancies.
What is the current status of trial NCT00089245?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 177 participants. The study started on 2004-02-05. Estimated completion is 2022-02-02.
What interventions are being tested in trial NCT00089245?
The interventions under investigation include: Iodine I 131 MOAB 8H9 (DRUG).
Who is sponsoring clinical trial NCT00089245?
This trial is sponsored by Y-mAbs Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.